Use of AAM for Correction of Age Related Volume Deficits in the Face
Primary Purpose
Age-Related Atrophy
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
AAM
Sponsored by
About this trial
This is an interventional treatment trial for Age-Related Atrophy
Eligibility Criteria
Inclusion Criteria:
- Men or women, 30-70 years of age
- Has overall mid-facial volume deficit of Grade 3 or 4 on Medicis Midface Volume Scale (MMVS)
- Willingness and ability to provide written informed consent
- Has not had AAM injected above the neck
- Ability to understand and comply with the requirements of the study
- Negative urine pregnancy test results at the time of study entry (if applicable).
- Willingness to stay on consistent and current skin care regimen for the duration of the study
- Willingness to maintain consistent and current diet and exercise for the duration of the study
- Willingness to forego any cosmetic augmentation procedure for the duration of the study
- Willingness to be photographed for educational, medical publication and other non-commercial purposes
- Has BMI ≥18 and ≤30
Exclusion Criteria:
- A subject with any uncontrolled systemic disease.
- A subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study.
- A subject with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
- Women that are pregnant, nursing, or planning a pregnancy during the duration of the study
- A subject that has had AAM injected above the neck
- A subject unwilling to be photographed for educational, medical publication and other non-commercial purposes
- A subject with a history of diabetes
- A subject with known hypersensitivity to any of the components of AAM
- A subject that has had, or who knowingly will have, dental work +/- 4 weeks prior to, or following AAM injection
- A subject using any systemic corticosteroid or immunosuppressive medications within 30 days prior to treatment and topical steroids on the face within 14 days prior to treatment and throughout the study
- A subject that has participated in another research study within 30 days of enrollment in this study
- A subject that is unwilling to forego any cosmetic augmentation treatment for the duration of the study
- A subject that has been treated with Botulinum Toxin below the orbital rim within 6 months of study entry.
- A subject that is unwilling to forego cosmetic facial treatments for the duration of the study
- A subject that has received Sculptra in the treatment area
- A subject that has received dermal filler in the treatment area within 2 years prior to randomization
- A subject that has previously undergone mid-face cosmetic plastic surgery, tissue grafting, or tissue augmentation with silicone, semi-permanent fillers or fat
- A subject that has previously undergone laser resurfacing, intense pulsed light treatment, chemical peel, or other ablative or non-ablative treatment within 6 months
- Subject is immunocompromised or immunosuppressed
- History of keloid formation or hypertrophic scars
- NSAID or Aspirin, other than a stable low dose aspirin regimen, within 1 week (7 days) prior to treatment
- Concomitant anticoagulant therapy, antiplatelet therapy, or history of bleeding disorders or connective tissue disorders
- A subject with recent excessive facial exposure to sunlight or artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing)
- A subject with a recent history or active presence of any facial skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e. moderate to severe acne vulgaris, atopic dermatitis, psoriasis, rosacea, seborrheic dermatitis, excessive facial hair or coloration)
- Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study
- A subject not deemed to be enrolled at the discretion of the surgeon investigator
Sites / Locations
- Aesthetic Eyelid Plastic Surgery
- Tennessee Clinical Research Center
- Dallas Plastic Surgery Institute
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Allograft Adipose Matrix (AAM) 1.0
Allograft Adipose Matrix (AAM) Diluted
Arm Description
Outcomes
Primary Outcome Measures
Volume change for the treated areas using the validated 4 point MEDICIS Mid-Face Volume Scale Assessment (MMVSA) at 24 weeks post-treatment compared to pre-treatment
MMVSA measures facial volume deficit, ranging from 1 (fairly full midface) to 4 (substantial loss of fullness in the midface area). Lower values represent a better outcome.
Three-D facial photography (Canfield) with computation of volume changes at 24 weeks compared to pre-treatment.
Secondary Outcome Measures
Duration of effectiveness when the average of the Evaluating Investigators' live assessments of the MMVSA scale will return to, or be worse than, the pre-treatment level over 24 weeks post-treatment.
MMVSA measures facial volume deficit, ranging from 1 (fairly full midface) to 4 (substantial loss of fullness in the midface area). Lower values represent a better outcome.
Volume change assessments using the Global Aesthetic Improvement Scale (GAIS) at 24 weeks post-treatment compared to pre-treatment
GAIS rates improvement in appearance. Scores range from 0 (worse) to 4 (very much improved). Higher values represent a better outcome.
Full Information
NCT ID
NCT03652844
First Posted
August 28, 2018
Last Updated
May 7, 2021
Sponsor
Musculoskeletal Transplant Foundation
1. Study Identification
Unique Protocol Identification Number
NCT03652844
Brief Title
Use of AAM for Correction of Age Related Volume Deficits in the Face
Official Title
A Multi-Phase, Prospective, Multi-Center, Single-Blind, Clinical Study to Evaluate the Safety and Efficacy of Allograft Adipose Matrix (AAM) and Diluted AAM for Pre-Jowl and Malar Augmentation to Correct Age Related Volume Deficit in the Face
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
August 27, 2018 (Actual)
Primary Completion Date
July 12, 2019 (Actual)
Study Completion Date
July 12, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Musculoskeletal Transplant Foundation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate Allograft Adipose Matrix (AAM) in the face of people with age-related volume deficit - fat loss. AAM is a tissue used to correct fat loss. Participation in this study requires injections for placing AAM in the bilateral pre-jowl and malar areas of the face. The research will tell whether AAM is effective in maintaining mid-face fullness and whether the appearance of the skin improves after injection.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Age-Related Atrophy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized cohorts
Masking
Participant
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Allograft Adipose Matrix (AAM) 1.0
Arm Type
Active Comparator
Arm Title
Allograft Adipose Matrix (AAM) Diluted
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
AAM
Intervention Description
Subcutaneous injection procedure
Primary Outcome Measure Information:
Title
Volume change for the treated areas using the validated 4 point MEDICIS Mid-Face Volume Scale Assessment (MMVSA) at 24 weeks post-treatment compared to pre-treatment
Description
MMVSA measures facial volume deficit, ranging from 1 (fairly full midface) to 4 (substantial loss of fullness in the midface area). Lower values represent a better outcome.
Time Frame
24 weeks
Title
Three-D facial photography (Canfield) with computation of volume changes at 24 weeks compared to pre-treatment.
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Duration of effectiveness when the average of the Evaluating Investigators' live assessments of the MMVSA scale will return to, or be worse than, the pre-treatment level over 24 weeks post-treatment.
Description
MMVSA measures facial volume deficit, ranging from 1 (fairly full midface) to 4 (substantial loss of fullness in the midface area). Lower values represent a better outcome.
Time Frame
24 weeks
Title
Volume change assessments using the Global Aesthetic Improvement Scale (GAIS) at 24 weeks post-treatment compared to pre-treatment
Description
GAIS rates improvement in appearance. Scores range from 0 (worse) to 4 (very much improved). Higher values represent a better outcome.
Time Frame
24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Men or women, 30-70 years of age
Has overall mid-facial volume deficit of Grade 3 or 4 on Medicis Midface Volume Scale (MMVS)
Willingness and ability to provide written informed consent
Has not had AAM injected above the neck
Ability to understand and comply with the requirements of the study
Negative urine pregnancy test results at the time of study entry (if applicable).
Willingness to stay on consistent and current skin care regimen for the duration of the study
Willingness to maintain consistent and current diet and exercise for the duration of the study
Willingness to forego any cosmetic augmentation procedure for the duration of the study
Willingness to be photographed for educational, medical publication and other non-commercial purposes
Has BMI ≥18 and ≤30
Exclusion Criteria:
A subject with any uncontrolled systemic disease.
A subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study.
A subject with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
Women that are pregnant, nursing, or planning a pregnancy during the duration of the study
A subject that has had AAM injected above the neck
A subject unwilling to be photographed for educational, medical publication and other non-commercial purposes
A subject with a history of diabetes
A subject with known hypersensitivity to any of the components of AAM
A subject that has had, or who knowingly will have, dental work +/- 4 weeks prior to, or following AAM injection
A subject using any systemic corticosteroid or immunosuppressive medications within 30 days prior to treatment and topical steroids on the face within 14 days prior to treatment and throughout the study
A subject that has participated in another research study within 30 days of enrollment in this study
A subject that is unwilling to forego any cosmetic augmentation treatment for the duration of the study
A subject that has been treated with Botulinum Toxin below the orbital rim within 6 months of study entry.
A subject that is unwilling to forego cosmetic facial treatments for the duration of the study
A subject that has received Sculptra in the treatment area
A subject that has received dermal filler in the treatment area within 2 years prior to randomization
A subject that has previously undergone mid-face cosmetic plastic surgery, tissue grafting, or tissue augmentation with silicone, semi-permanent fillers or fat
A subject that has previously undergone laser resurfacing, intense pulsed light treatment, chemical peel, or other ablative or non-ablative treatment within 6 months
Subject is immunocompromised or immunosuppressed
History of keloid formation or hypertrophic scars
NSAID or Aspirin, other than a stable low dose aspirin regimen, within 1 week (7 days) prior to treatment
Concomitant anticoagulant therapy, antiplatelet therapy, or history of bleeding disorders or connective tissue disorders
A subject with recent excessive facial exposure to sunlight or artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing)
A subject with a recent history or active presence of any facial skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e. moderate to severe acne vulgaris, atopic dermatitis, psoriasis, rosacea, seborrheic dermatitis, excessive facial hair or coloration)
Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study
A subject not deemed to be enrolled at the discretion of the surgeon investigator
Facility Information:
Facility Name
Aesthetic Eyelid Plastic Surgery
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33431
Country
United States
Facility Name
Tennessee Clinical Research Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37215
Country
United States
Facility Name
Dallas Plastic Surgery Institute
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Use of AAM for Correction of Age Related Volume Deficits in the Face
We'll reach out to this number within 24 hrs